1 / 46

Speaker Disclosure

CRRT in Liver Failure Akash Deep Director - PICU King’s College Hospital London Chair Renal/CRRT Section European Society of Pediatric and Neonatal Intensive Care (ESPNIC). 0. Speaker Disclosure. Overview. AKI and CRRT in ALF CRRT in CLD/ AoCLF Role of MARS and TPE in Liver failure

rorys
Download Presentation

Speaker Disclosure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CRRT in Liver FailureAkash DeepDirector - PICU King’s College HospitalLondonChairRenal/CRRT SectionEuropean Society of Pediatric and Neonatal Intensive Care (ESPNIC) 0

  2. Speaker Disclosure

  3. Overview • AKI and CRRT in ALF • CRRT in CLD/ AoCLF • Role of MARS and TPE in Liver failure • Anticoagulation in liver Patients

  4. RRT in liver patients ALF AoCLF Post Liver Transplant Metabolic disease- hyperammonaemia, primary hyperoxaluria CRRT – standard ICU indications in patients with liver disease

  5. Survival in patients treated by RRT according to diagnoses: ppCRRT Registry Symons, Clin J Am SocNephrol, 2: 732, 2007 pCCRT Rome 2010

  6. CRRT in ALF

  7. ELAD ? ? Bridging means identifying which patient is sufficiently lucky to survive

  8. Why use liver support? • Survival ? • Improved Cardiovascular Stability • Improved HE, decreased ammonia • Control fluid balance (before/after ELT) • Increase delay to ELT, bridge to ELT • Standard use in ICU setting • Conducive Environment for Either Liver Regeneration /Liver Transplant Hepatology 1998:27:1050-5

  9. Controversies in RRT in Liver Failure • Why do patients with Liver failure develop AKI? • What is the best time to initiate RRT in patients with ALF? - Elective versus standard CRRT • What dose of RRT is the best dose? • Anticoagulation in CRRT for ALF • Ideal Extracorporeal Liver Assist Device (ELAD) – excretory and synthetic function

  10. Mechanisms of AKI in ALF • Multifactorial • Pre-renal AKI • Acute tubular necrosis due to profound hypovolemia and hypotension • Direct drug nephrotoxicity (paracetamol, NSAIDs) • Hepatorenal syndrome • Intra-abdominal hypertension (IAH) and development of abdominal compartment syndrome

  11. Pathogenesis of AKI in ALF Arterial vasodilatation (‘’VASOPLEGIA’’) Decreased SVR High Cardiac Output Renal Auto-regulation becomes Pressure Dependent - Intra-renal Vasoconstriction

  12. Why patients with FHF die ? • Cerebral edema/intracranial hypertension • Sepsis – MOSF • SIRS at presentation associated with mortality - immune modulation

  13. Ammonia levels and its brain delivery predicts brain swelling and advanced HE Clemmesen et al. Bernal et al. Hepatology, 2007 Jalan et al. J Hepatology; 2004 Oct;41(4):613-20 Bhatia et al. Gut. 2006 Jan;55(1):98-104.

  14. Evidence for Ammonia Comparison of arterial ammonia levels at admission between survivors and non‐ survivors among acute liver failure patients Gut. 2006 January; 55(1): 98–104

  15. Hyponatremiapotentiateammoniaeffect on HE Gines et al Hepathology 2008

  16. WITH 35 MLS/KG/HR - At 1 hour AC – 39 AND AT 24 HOURS – 44MLS/MIN WITH 90 MLS/KG/HR – AT 1 HOUR – 85 AND AT 24 HOURS 105 MLS/MIN . Ammonia clearance is closely correlated with ultrafiltration rate. HF was associated with a fall in arterial ammonia concentration

  17. HVHF - > 80mls/kg ultrafiltrate, Median flow of ultrafiltrate was 119 mL/kg/hr(80– 384). After 48 hours of treatment, mean arterial pressure (p = 0.0005), grade of hepatic encephalopathy (p = 0.04), and serum creatinine Overall mortality was 45.4% (n = 10). Emergency liver transplantation was performed in eight children. Five patients spontaneously recovered liver function

  18. Authors – Akash Deep, Anil Dhawan

  19. RRT – Indications in ALF • Hepatic encephalopathy grade 3-4 • NH3 >150 µmol/litre and not getting controlled or an absolute value >200 µmol/litre • Renal dysfunction (Oligo-anuria, Hyperkalemia, fluid overload) • Metabolic abnormalities ( hyponatremia Na <125 meq/litre, High lactate and increasing despite optimising fluid therapy, Metabolic acidosis) No one indication is an absolute one for initiation of RRT

  20. Primary outcome : Survival to hospital discharge with or without liver transplantation • Secondary outcome: arterial ammonia, lactate, percentage fluid overload, creatinine and mean arterial pressure

  21. Box plot of the trend in ammonia level (umol/L) by survival.

  22. Kaplein Meier 60 day survival curves according to age- CRRT pts < 1 year and > 1 year <1 gray >=1 black P=0.0095 Y = probability of survival X = time in days

  23. Kaplan Meier Curve for CRRT pts no transplant; shows improved survival with CRRT severity adjusted by PELD Non CRRT dotted CRRT solid p=0.002 Y = probability of survival X = time in days Since transplantation interferes with the natural progression of PALF; analysed pts didn’t undergo transplant; Severity adjusted for case mix with PELD

  24. Kaplan Meier Curve for Survival of PELD Adjusted PALF on CRRT – Severity by PELD Score; <2011 dotted >= 2011 solid P= 0.4 (not) Y = probability of survival X = time in days

  25. HV-CVVH in Pediatric FHF • Reduces ELT requirement ? • Improved hemodynamic, renal and neurological function • Allows a prolonged delay to ELT ?

  26. Continuous vv hemofiltration and plasma exchange in infantile ALF - NCCH, Tokyo, Japan 17 infants, 88% survival Ide and coll. PCCM Accepted

  27. Modalities • CRRT – CVVH, CVVHD, CVVHDF – no evidence which is better • TPE – Therapeutic Plasma Exchange • MARS • SPAD – Single Pass Albumin Dialysis

  28. MARS

  29. SURVIVAL

  30. Courtesy – Fin Larsen

  31. Courtesy – Fin Larsen

  32. Courtesy – Fin Larsen Ideal ELAD – Tackles synthetic and excretory dysfunction

  33. SUMMARY No Evidence for RRT in Liver patients Should we undertake CRRT in ALF Yes - and review : population data vs individual care Why ? –Neuro-protection, metabolic disarray, bridge for recovery or transplant When Earlier - need new markers Mode CRRT – unstable, TPE coming in fashion !! Access sites Internal Jugular Dose No evidence in Paediatrics High – gaining popularity Anticoagulation - YES PGI2 and /or low dose heparin

  34. RRT in CLD / AoCLF • Mainstay of supportive therapy for patients who deteriorate despite aggressive resuscitation • Volume overload, intractable metabolic acidosis, and hyperkalemia • Delay in RRT – MORTALITY > 90% • High risk in hepatic encephalopathy, hypotension, and coagulopathy • Serves as bridge to transplant • If RRT > 8 weeks before LT - ???? Combined Liver-Kidney Transplantation

  35. Anticoagulation Anticoagulation in RRT in liver patients – is it different ? Should CRRT circuits in patients with hepatic failure be anti-coagulated?

  36. Background :Coagulopathy & Liver Disease • INR, PT, aPTT • "rebalanced haemostasis"

  37. No Anticoagulation • Low dose Heparin • Prostacyclin • Citrate ??? HEPARIN PROSTACYCLIN

  38. CVVHD + regional citrate in liver failure Observational study Schultheiss C et al Crit Care 2012 • Accumulation in citrate correlated with an increase in Catot/Caion • Critical ratio of 2.5 exceeded 10 times (of 273) in 7 of 43 runs; • Seen at 12 hours(3), 24 hours (6) and 1 at 72 hours • Equalization of acid base was possible • Standard lab values did not correlate with citrate accumulation ratio > 2.5 • Lactate > 3.5 mmol/L or prothrombin ratio < 26% • Predict ratio Catot/Caion > 2.5 • Sensitivity 86% for both • Specificity of 86% for lactate and 92% for prothrombin

  39. Schultheiss C et al Crit Care 2012 16:R162 Decreased citrate clearance in cirrhosis 340 ml/min Vs 710 ml/min in normals Krammer et al 2003 ? Option of CVVHD vs CVVHF the former allowing lower blood flow and greater clearance of citrate 29 fold increase in citrate

  40. CRRT in Liver Disease • Different from non-liver ICU patients • Indications • Timing • ?Dose – Role of HVHF • Role of TPE – is there a role in combining TPE with CRRT ?? • Anticoagulation • Main Role – Bridge to LT or spontaneous recovery

More Related